Tideglusib
Tideglusib is a pharmaceutical drug with 9 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
7
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
5 of 5 finished
0.0%
0 ended early
2
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy
Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy
Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy
Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders
Clinical Trials (9)
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy
Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy
Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy
Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis
Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients
Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9